Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
about
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsComparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort studyDosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany.Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based studyA Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.The impact of Medicare prescription drug coverage on the use of antidementia drugs.Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy.Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistenceObservational cohort study: deprivation and access to anti-dementia drugs in the UK.Donepezil Adherence, Persistence and Time to First Discontinuation in a Three-Year Follow-Up of Older People.Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled studyPharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Variations in self-reported practice of physicians providing clinical care to individuals with dementia: a systematic review.Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice.Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea.Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis.The effect of telemedicine on the duration of treatment in dementia patients.Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.Clinical compliance of donepezil in treating Alzheimer's disease in taiwan.Patterns and Determinants of Dementia Pharmacotherapy in a Population-Based Cohort of Home Care Clients
P2860
Q26997299-1F30A118-057E-4215-A876-66821FE95E10Q28542423-4595FE4F-3969-4D50-A380-06B18D6F50FDQ30683521-90DB7C4F-ED25-4157-B69E-1A11DF165640Q33718205-3A90D9A3-5098-4D56-889C-AFE2A281899EQ33736233-1DEA2FD5-0451-4491-8B7B-A24580C55571Q34690333-B7F72B1B-9C0D-4582-9117-D85397255625Q34982153-AA5D6677-43B7-46BD-932A-131CB5AB4B22Q35006354-95B9DBB4-3CCE-4808-B53D-56FAF2D0658AQ36222012-3B0C7F5F-4D4B-4FDE-8EEC-AC8F2B1E55C5Q36459047-E0FB7A8D-8FA0-40C3-B20B-9E6A64BB475EQ36650679-C4FA65A7-DB4B-466D-B805-0F774511CD4AQ37417244-CC88878A-E618-4FAC-AA23-FFD48ECAA7DBQ37693772-7D5B40CE-AB09-47E6-BB3C-8F03DF92E266Q38124387-75F20271-FC52-445B-96BD-C7DF122ADFFDQ38182842-41E52866-F082-4523-A48E-3C4272C1EBCFQ38261855-0643D2FD-D52D-4B3C-B7E0-DA2A8165D33AQ39466063-77E570FA-285C-40D3-8B16-79BAE7E1A774Q41032305-8F19D5F3-2AA6-4BBC-9028-137969446E8CQ41585342-E41F4A4E-725C-408E-94D3-9179FC3BE53BQ42332050-78282AAC-148B-4C3B-96FF-990D447A4D92Q43293526-0C0930BE-BB42-45A8-ACB4-40C20BB2E183Q44716353-1B192389-4FC1-4002-ACED-F0C4C1A77405Q50614178-7867EA97-B32F-4821-804F-3AD7EBC039CFQ57244256-9489776B-3152-41F3-9A5B-9812395E14AC
P2860
Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Persistence with cholinesteras ...... ents with Alzheimer's disease.
@en
Persistence with cholinesteras ...... ents with Alzheimer's disease.
@nl
type
label
Persistence with cholinesteras ...... ents with Alzheimer's disease.
@en
Persistence with cholinesteras ...... ents with Alzheimer's disease.
@nl
prefLabel
Persistence with cholinesteras ...... ents with Alzheimer's disease.
@en
Persistence with cholinesteras ...... ents with Alzheimer's disease.
@nl
P2093
P2860
P356
P1476
Persistence with cholinesteras ...... ents with Alzheimer's disease.
@en
P2093
Alison Supina
Colleen J Maxwell
Joseph E Amuah
Misha Eliasziw
Patricia Beck
Winanne Downey
P2860
P304
P356
10.1002/PDS.1946
P577
2010-07-01T00:00:00Z